Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Franklin Resources Inc.

Franklin Resources Inc. lifted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 34.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 243,760 shares of the company’s stock after buying an additional 62,178 shares during the quarter. Franklin Resources Inc.’s holdings in Krystal Biotech were worth $43,774,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in KRYS. Blue Trust Inc. boosted its stake in shares of Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of Krystal Biotech by 11.1% during the second quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock worth $173,000 after buying an additional 94 shares during the period. Louisiana State Employees Retirement System acquired a new stake in shares of Krystal Biotech during the second quarter worth about $2,296,000. EFG Asset Management North America Corp. lifted its position in Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in Krystal Biotech by 115.7% in the second quarter. Bank of New York Mellon Corp now owns 193,767 shares of the company’s stock valued at $35,583,000 after purchasing an additional 103,928 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on KRYS shares. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Chardan Capital restated a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research report on Thursday, December 12th. Stifel Nicolaus raised their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Citigroup increased their target price on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a research note on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Krystal Biotech has a consensus rating of “Buy” and an average target price of $206.67.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.10% of the stock is owned by corporate insiders.

Krystal Biotech Stock Performance

KRYS stock opened at $169.04 on Wednesday. The stock has a market capitalization of $4.86 billion, a P/E ratio of 95.50 and a beta of 0.80. Krystal Biotech, Inc. has a one year low of $107.50 and a one year high of $219.34. The company has a 50 day moving average price of $181.01 and a two-hundred day moving average price of $185.37.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue for the quarter was up 879.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.67) EPS. Research analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).